Other publications concerning MPN;s by members of the NMPN from 2000

Denmark

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012 Aug 6. [Epub ahead of print]

Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol. 2012 Jun 1. [Epub ahead of print]

Kjær L, Westman M, Hasselbalch Riley C, Høgdall E, Weis Bjerrum O, Hasselbalch H. A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. PLoS One. 2012;7(3):e33100. Epub 2012 Mar 5.

Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012 Apr 5;119(14):3219-25.

Madelung A, Bzorek M, Bondo H, Zetterberg E, Bjerrum OW, Hasselbalch HC, Scheding S, Ralfkiaer E. A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis. Histopathology. 2012 Mar;60(4):554-60. doi: 10.1111/j.1365-2559.2011.04104.x. Epub 2012 Jan 17.

Andersen CL, Hasselbalch H, Grønbæk K Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. Leuk Res. 2012 Apr;36(4):485-7.

Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with interferon-alpha. Blood. 2011 Jun 27. [Epub ahead of print]

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives. Current Drug Targets. 2010 Dec 14. [Epub ahead of print]

Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS, Hasselbalch H, Vannucchi AM, Moller P, Dohner K, Green A. Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica 2010;95(12):2153-2156.

Hasselbalch HC. Myelofibrosis with Myeloid Metaplasia. The Advanced Phase of an Untreated, Disseminated Hematological Cancer. Time to Change Our Therapeutic Attitude with Early Upfront Treatment: Leukemia Research 2009;33:11-8.

Larsen TS, Pallisgaard N, de Stricker K, Moller MB, Hasselbalch HC. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology 2009;14(1): 11-5.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 2008;22(1):194-5.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. High High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: Independence of the V617F allele burden. Hematology 2008;13(2):71-6.

Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatly K, Buck G, Harrison C, Green AR. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008; May 1. (Epub ahead of print).

Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC, Le Bousse-Kerdiles MC. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence . Blood 2008; Epub ahead of print.

Hasselbalch HC & Riley CH. The mevalonate pathway as a therapeutic target in the treatment of chronic myeloproliferative disorders. Current Drug Targets, 2007; 8(2):247-56.

Larsen TS, Pallisggaard N, Hasselbalch HC, Kerndrup GB. A der 8)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. Cancer Genet Cytogenet 2007;172(2):107-12.

Larsen TS, Pallisgaard N, Hasselbalch HC. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136(5):745-51.

Larsen TS, Hasselbalch HC, Pallisgaard N, Møller MB. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. APMIS 2007;115(11):1267-73.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.The JAK2V617F allele burden in essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis- impact on disease phenotype. Eur J Haematol 2007;79(6):508-15.

Campbell P, Griesshammer H, Dohner K, Dohmer H, Kusec R, Hasselbalch
HC, Larsen TS, Pallisgaard N, Giraudier S et al. The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107(5):2098-2100.

Hasselbalch HC & Riley CH. Statins in polycythaemia vera and allied disorders. A cytoreductive and anti.thrombotic potential? Leukemia Research 2006;30(10):1217-23.

Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies,cytogenetic associations and role in leukemic transformation. Blood 2006;108:3548-55.

Penninga EI, Bjerrum OW. Polycythaemia vera and essential thrombocythaemia: current treatment strategies. Drugs. 2006;66(17):2173-87.

Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ, Hasselbalch HC. Anagrelide treatment of thrombocytosis in 55 patients with chronic myeloproliferative disorders. Clin Lab Haematol 2004;26(5):335-40.

Nielsen I & Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Ph-negative chronic myeloproliferative disorder treated with hydroxyurea alone or hydroxyurea following busulphan. A clinical study of 86 patients. Am J Hematol 2003;74(1):276-82.

Hasselbalch HC, Jensen BA, Tøffner Clausen NAA, Hansen PB, Therkelsen MH, Ralfkjær E, Birgens H, Bjerrum OW. Imatinib mesylate in the treatment of idiopathic and postpolycythemic myelofibrosis Am J Hematol 2003;74(4):238-42.

Hasselbalch HC. SU6668 in idiopathic myelofibrosis - a rational therapeutic
approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. Medical Hypothesis. Medical Hypotheses 2003;61(2):244-7.

Jensen MK, Madsen RR, Holten-Andersen MN, de Nully Brown P, Junker P, Brunner N, Hasselbalch HC. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders. Correlation between plasma soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol 2003;71(4):276-82.

Jensen MK, Holten-Andersen MN, de Nully Brown P; Larsen MB, Kjeldsen LK, Heickendorff, Brunner N, Hasselbalch HC. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders.Eur J Haematol 2003;71(5):377-84.

Hasselbalch HC, Tøffner Clausen NAA , Jensen BA,. Successful treatment of
anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 2002;70:92-99.

Jensen MK, Madsen RR, Holten-Andersen MN, de Nully Brown P, Brunner N, Hasselbalch HC. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis and polycythaemia vera. Eur J Haematol. 2002;69(1):43-9.

Jensen MK, de Nully Brown P, Thorsen S, Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies , factor V Leiden mutation and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol 2002;(69):185-91.

Jensen MK, Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet. Eur J Haematol 2001;66(3):143-51.

Hasselbalch HC. A possible role of STI571 in the treatment of idiopathic
myelofibrosis. Am J Hematol 2001;68(1):63-4.

Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch H. High prevalence of hyperhomocysteinemia in chronic myeloproliferative disorders. Am J Hematol 2000; 65(2):136-40.

Jensen MK, Brown P,Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders Br J Haematol 2000;110:116-124.

Jensen MK, Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a geographical area. Eur J Haematol 2000;65(2):132-9.

Finland
Mustjoki S, Borze I, Alitalo R, Lasho TL, Pardanani A, Sakari Knuutila S, and Juvonen E. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythemia or polycythemia vera. Leukemia Research 2009, in press Borze I, Mustjoki S, Juvonen E, Knuutila S. Oligoarray CGH in polycythemia vera and essential thrombocythemia. Haematologica 2008;93:1098-1100.

Niittyvuopio R, Juvonen E, Kekomäki R, Oksanen K, Anttila P, Ruutu T. The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complictions in essential thrombocythaemia. Eur J Haematol 2004;72:245-251.

Niittyvuopio R, Juvonen E, Kaaja R, Oksanen K, Hallman H, Timonen T, Ruutu T. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol 2004;73:431-436.

Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplantation 2002;29:457-458.

Sweden
Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Björkholm M. Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. J Clin Oncol. 2012 Jul 16. [Epub ahead of print

Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B.Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012 Mar;53(3):441-4.

Khadija Abdulkarim, Börje Ridell, Peter Johansson, Jack Kutti, Soodabeh Safai-Kutti, Björn Andréasson. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 2010;86:148–155.

Thiele J, Kvasnicka HM, Vardiman JW, Orazi A, Franco V, Gisslinger H, Birgegard G, Griesshammer M, Tefferi A. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol. 2009;27(34):e220-1.

Goldin LR, Björkholm M, Kristinsson SY, Samuelsson J, Landgren O. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med; 2009;29;1(5):55.

Birgegård G. New perspectives in managing myeloproliferative disorders: focus on the patient.Hematol Oncol. 2009;27 Suppl 1:5-7

Birgegård G. Long-term management of thrombocytosis in essential thrombo-cythaemia. Ann Hematol. 2009;88:1-10.

Abdulkarim K, Girodon F, Johansson P, Maynadié M, Kutti J, Carli PM, Bovet E, Andréasson B AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol. 2009;82(2):106-11.

Tobiasson M, Alyass B , Söderlund S, Birgegård G. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Accepted for publication in Medical Oncology 2009 Feb 19 [Epub ahead of print].

Swolin B, Rodjer S, Westin J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Ann Hematol 2008; 87(6):467-74.

Zetterberg E, Popat U, Hasselbalch H, Prchal J, Palmblad J.Angiogenesisin pulmonary hypertension with myelofibrosis. Haematologica 2008;93:945-6.

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.Exp Hematol 2007;35(11):1695-703.

Birgegård G. Essential thrombocythaemia treatment options: addressing patient-specific needs. Eur J Haematol;Suppl. 2007;(68):27-31.

Zetterberg E, Vannucchi AM, Migliaccio RM, Vainchenker W,, Tulliez M, Dickie, R, Rogers R, Palmblad J. Pericyte coverage of abnormal vessels in myelofibrosis bone marrows. Haematologica 2007;92:597-604.

Birgegard G. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 2006;32(3):260-66.

Johansson P. Epidemiology of the myeloproliferative disorders PV and ET. Semin Thromb Hemost 2006;32:171-173.

Johansson P, Andréasson B. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera. Clin Lab Haematology 2006;28:233-236

Finazzi G, Caruso V, Marchioli R, Capnist G, Chiesi T, Finelli C, Gugliotta L, Landolfi P, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognioni G, Barbui T. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670.

Johansson P, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis. a study of patients with polycythaemia vera and apparent polycthaemia. British Journal of Haematology 2005;129:701-705

Goerttler P, März E, Johansson P, Andréasson B, Kutti J, Moliterno A, Marchioloi R, Spivak J, Pahl H. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-MPL protein expression and PRV-1 mRNA levels. Haematologica 2005;90:851-853

Goerttler P, Steimle C, März E, Johansson P, Andréasson B, Griesshammer, Gisslinger H, Heimpel H, Pahl H. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-2864

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognioni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-2232.

Johansson P, Brudin G, Nilsson B and Andréasson B. Oxygen affinity is decreased in patients with polycythaemia vera and essential thrombocythaemia. Scand J Clin Lab Invest 2004;64:71-76.

Landolfi R, Marchioli P, Kutti J, Gisslinger H, Tognioni G, Patrono C, Barbui T. Efficacy and safety of lowdose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.

Palmqvist L, Goerttler P, Wasslavik C, Johansson P, Andreasson B, Safai-Kutti S, Kutti J, Pahl H and Ricksten A. Method comparision of PRV-1 mRNA quantification in whole blood leukocytes and purified granulocytes. Clin Chem 2004;50:644-647

Johansson P, Kutti J, Andréasson B, Safai-Kutti S, Vilén L and Wedel H. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Int Med 2004;256:161-165

Johansson P, Ricksten A, Wasslavik C, Johansson B, Andréasson B. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera. Haematologica 2004;89:1264-1266

Michiels JJ, Bernernan Z, Schroyens W, Kutti J, Swolin B, Ridell B, Fernando P, Zanetto U. Philadelphia (Ph) chrornosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrornbocythemia. Ann Hematol 2004;83: 504-512.

Zetterberg E, Lundberg LG, Palmblad J. Characterization of blood vessels in bone marrow from patients with chronic myeloid leukemia and polycythemia vera. Scand J Clin Lab Invest 2004;64:641-648.

Andréasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentrations are independent risk factors for thromboembolic complications in essential thrombocythemia. Blood 2003;101:783-784.

Johansson P, Andreasson B, Safai-Kutti S, Wennström L, Palmqvist L , Ricksten A, Lindstedt G and Kutti J. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia. Eur J Haemat 2003;70:358-362

Johansson P, Ricksten A, Wennström L, Palmqvist L, Kutti J and Andréasson B. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol 2003;123:513-516

Zetterberg E, Lundberg LG, Palmblad J. Expression of cox-2, tie-2 and glykodelin by megakaryocytes in patients with chronic myeloid leukaemia and polycythemia vera. Br J Haematol 2003;121:495-499.

Andréasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34' cell concentrations in periphral blood compared to patients with polycythaemia vera and essential thrombocythaenlia. Eur J Haernatol 2002;68:189-193.

Johansson P, Andreasson B, Safai-Kutti S, Rhedin C, Vilén L, Kutti J. On the diagnosis of polycythaemia vera as assessed in the health and medical care in the Västra Götaland region, Sweden. J Intl Med 2002;251:348-354

Johansson P, Safai-Kutti S, Lindstedt G, Suurküla M, Kutti J. The red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythemia. Acta Haematol 2002;108:1-7

Andréasson B, Lindstedt G, Stockelberg D, Wadenvik H, Kutti J. The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia. Leuk Lyrnphorna 2001;41:574-5 84.

Folkman J, Browder T, Palmblad J: Angiogenesis research: Guidelines for translation to clinical application. Thromb Heamost 2001; 86:23-33

Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol 2001;49:164-166.

Swolin B, Safai-Kutti S, Anghem. E, Kutti J. No increased frequency of trisomies 8 and 9 by fluorescence in situ. hybridization in untreated patients with essential thrombocythaemia. Cancer Genet Cytogenet 2001;126: 56-59.

Andersson PO, Ridell B, Wadenvik H, Kutti J. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol 2000;79: 40-42.

Andréasson B, Cameskog J, Lindstedt G, Lundberg P-A, Swolin B, Wadenvik H, Kutti J. Plasma erythropoietin concentrations in polycythaemia vera with special reference to myelosuppressive therapy. Leuk Lymphoma 2000;37:189-195.

Andréasson B, Swolin B, Kutfi J. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD positive cells in polycythaemia vera and essential thrombocythaernia. Eur J Haernatol 2000;64:188-193.

Andréasson B, Lindstedt G, Kutti J. Plasma erydropoietin in essential thrornbocythaernia: at diagnosis and in response to rnyelosuppressive treatment. Leuk Lymphorna, 2000;38:113-120.

Le Blanc K, Andersson P & Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythemia vera. Br J Haematol 2000;108:80-5.

Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.

Michiels D, Barbui T, Finazzi G, Fruchtinan SM, Kutti J, Rain L-D, Silver RT, Tefferi A, Thiele J. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma 2000;36:239-253.

Ridell B, Carneskog J, Wedel H, Vilén L, Hogh Dufva 1, Mellqvist U-H, Brywe N, Wadenvik H, Kutti J. Incidence of chronic myeloproliferativ.e disorders in the city of Göteborg, Sweden 1983-1992. Eur J Haematol 2000;65:267-271.